AUSTIN, Texas, Feb. 15, 2011 /PRNewswire/ — Luminex Corporation
(Nasdaq:
LMNX) announced today that it has teamed with Partners
HealthCare toward the discovery of novel biomarkers and development
of clinical assays. This program will enable Partners
HealthCare Center for Personalized Genetic Medicine (PCPGM) to
develop novel molecular diagnostic assays based on biomarkers
discovered within Partners HealthCare entities. These
innovative tests will operate on Luminex’s proprietary xMAP®
testing platform. Under the terms of the agreement, Luminex
and PCPGM will evaluate opportunities for novel assays which will
be developed and validated in the PCPGM’s CLIA-certified Laboratory
for Molecular Medicine.
(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)
“The collaboration with Luminex represents an important step
forward in furthering Partners HealthCare Center for Personalized
Genetic Medicine’s mission to bridge the gap between research and
clinical medicine,” said Dr. Heidi Rehm, Director of PCPGM’s
Laboratory for Molecular Medicine at Partners HealthCare.
“Luminex’s xMAP technology provides an ideal platform for
Partners HealthCare to translate novel biomarker discoveries into
cutting-edge tests and accelerate adoption of new molecular tests
to provide the best clinical care for patients.”
The strength of the relationship between Luminex and PCPGM is
the resources, technologies and industry experience that each
organization offers, from research, development and the ability to
commercialize novel molecular diagnostic assays. By utilizing
Luminex’s xMAP technology, PCPGM can develop novel assays and bring
them from discovery to clinical diagnostics more efficiently and
cost-effectively.
“Luminex and Partners HealthCare have a shared
‘/>”/>
SOURCE